^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Oraxol (oral paclitaxel/encequidar) (Bcl2 inhibitor, Tubulin inhibitor, P-glycoprotein inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Confirmed tumor response by molecular subtype in patients with metastatic breast cancer: Sub-analysis from a phase 3 clinical study comparing oral paclitaxel and encequidar to IV paclitaxel.
Published date:
05/19/2021
Excerpt:
402 patients 2:1 to either oral paclitaxel and encequidar (oPac+E) or IV paclitaxel (IVPac)....Patients in the HR+/HER2- subgroup had a better tumor response to oPac+E (44.8% vs 21.4% IVPac-response rate difference of 23.4%)...
DOI:
10.1200/JCO.2021.39.15_suppl.1073
Trial ID:
